Vetoquinol SA, a veterinary pharmaceutical company, engages in designing, developing, and selling of veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA operates as a subsidiary of Soparfin SCA.
Frequently asked questions
What sector does Vetoquinol (VETO) operate in?
Vetoquinol belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Vetoquinol (VETO) current stock price?
As of the latest data, Vetoquinol stock price is €71.30, with a previous close of €71.30.
What is Vetoquinol (VETO) current market capitalization?
Vetoquinol market cap is approximately 828.84 million.
What is Vetoquinol (VETO) Earnings Per Share (EPS)?
The trailing EPS is €4.94, and the forward EPS is €5.64.
What is Vetoquinol (VETO) Price-to-Earnings (P/E) ratio?
Vetoquinol current P/E ratio is 14.43, with a forward P/E of 12.64.
Does Vetoquinol (VETO) pay dividends?
Yes. Vetoquinol pays annual dividends with an annualized yield of 1.3% and an estimated annual payout of €0.93 per share.
When is the next ex-dividend date for Vetoquinol (VETO)?
The next ex-dividend date is scheduled for June 03, 2027.
When is Vetoquinol (VETO) next earnings report?
Vetoquinol is expected to release its next earnings report on June 30, 2026.
What is Vetoquinol (VETO) beta (volatility) score?
Vetoquinol has a beta of 0.879, meaning its volatility is roughly in line with the market.
